Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (22002)	6/9/1998 6:19:00 AM
From: Henry Niman	Respond to of 32384

PB, I have linked analyst reports to the Analyst Tables at home.att.net One (I think Legg Mason) recently estimated that the SRGN/ONTAK buyout (including the manufacturing facility) would cost about 4 million shares.

To: Pseudo Biologist who wrote (22002)	6/9/1998 10:22:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Bear Stearns came out with European Drug Watch report yesterday. The think that the restructuring (buyout) of the MRK portion of the MRK/Astra JV will be announced late this week or early next. They also suggest that something may be happening with Novartis in the Life Science area. Norvartis CEO indicated that Norvartis remains "open to anything".

To: Pseudo Biologist who wrote (22002)	6/9/1998 10:28:00 AM
From: Andreas Helke	Read Replies (1) \| Respond to of 32384

I think that Ligand bought Seragen cheap enough to avoid dilution. There will be more Ligand shares. Together with the milestone payment it will be about 10%. But since there will be more revenue too and the Seragen shares disappear this does not dilute the Ligand stock. Andreas